The role of ubiquitination and deubiquitination in tumor invasion and metastasis

Shuangze Han1, Ruike Wang1, Yangnan Zhang1, Xiaoying Li1, Yu Gan1, Feng Gao2,3, Pengfei Rong1,2, Wei Wang1,2, Wei Li1,2

1. Department of Radiology, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, China
2. Cell Transplantation and Gene Therapy Institute, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China
3. Department of Ultrasonography, The Third Xiangya Hospital of Central South University, Changsha, Hunan, 410013, China

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).
See http://ivyspring.com/terms for full terms and conditions.

Received: 2021.11.24; Accepted: 2022.02.19; Published: 2022.03.06

Abstract

Ubiquitination is vital for multiple cellular processes via dynamic modulation of proteins related to cell growth, proliferation, and survival. Of the ubiquitination system components, E3 ubiquitin ligases and deubiquitinases have the most prominent roles in modulating tumor metastasis. This review will briefly summarize the observations and underlying mechanisms of multiple E3 ubiquitin ligases and deubiquitinases to regulate tumor metastasis. Further, we will discuss the relationship and importance between ubiquitination components and tumor progression.

Key words: ubiquitination; E3 ubiquitin ligase; deubiquitinase; metastasis

A brief overview of the ubiquitination process

Protein ubiquitination is a dynamic, multifaceted post-translational modification involved in multiple cellular processes. Ubiquitin (Ub), a 76-amino acid protein, features seven lysine residues (K6, K11, K27, K29, K33, K48, and K63), which can each be ubiquitinated to form distinctive forms of polyubiquitin chains. Different polyubiquitin chains mediate distinct signaling pathways to determine the fate of substrate proteins [1]. For example, K48/K11-linked chains are responsible for targeting substrate proteins for proteasomal degradation, while other chains perform non-degradative roles in controlling protein interactions, cellular localization, and signaling transduction (Fig. 1).

Ubiquitination is catalyzed by a three-enzyme cascade composed of the E1 Ub-activating enzyme, the E2 Ub-conjugating enzyme, and the E3 Ub ligase. E1 recruits and activates Ub by utilizing the energy of ATP. Activated Ub is transferred to E2, which can transfer Ub to the target substrate. E3 Ub ligase selectively recognizes a substrate protein by forming an iso-peptide bond between the COOH-terminal glycine of Ub and a lysine residue of the substrate. In addition, E3 Ub ligase recruits the E2-Ub complex and catalyzes the transfer of Ub to the substrate from E2 [2]. Different subtypes of E3s (the RING type E3s, the HECT type E3s, and the RBR type E3s) are the most critical component of the ubiquitination cascade for the substrate recognition capacity [2]. Meanwhile, ubiquitination is a dynamic and reversible process. Deubiquitinases (DUBs) can act as an “eraser” that reverses Ub signals. Most DUBs remove Ub moieties from proteins to prevent substrate proteins from degradation. However, some proteasome-related DUBs, including USP14, UCHL5, PSMD14, and PSMD7, are localized in 19S particles of the proteasome [3]. The roles of these DUBs are to deubiquitinate the substrates and facilitate their degradation in 20S particles of the proteasome. Alternatively, DUBs can alter signals by non-degradation ubiquitination [4] (Fig. 1).
The Ub cascade and DUBs synergistically regulate protein turnover and function in numerous signaling pathways to maintain cellular invasion and metastasis.

A novel insight into tumor metastasis

Tumor metastasis remains the primary cause of cancer-associated mortality. Metastasis involves tumor cell motility, intravasation into the adjacent tissues, circulation, and extravasation to distant organs. Simultaneously, the process is caused by genome instability where cancer cells can reprogram tumor metabolism, resist cell death, avoid immune destruction, and constitute the tumor microenvironment [5, 6]. The epithelial-mesenchymal transition (EMT) is an equally crucial determinant during the metastatic cascade [7].

Ubiquitination and deubiquitination broadly participate in various processes involved in protein modification and regulation. Aberrant dysregulation induces tumorigenesis. This review is primarily focused on recent novel observations and underlying mechanisms concerning E3 ligases and DUBs in order to contribute to further elucidating the role of ubiquitination and deubiquitination in tumor invasion and metastasis.

E3 Ub ligases inhibiting metastasis

F-box and WD-repeat domain-containing 2 (FBXW2)

FBXW2 is a substrate recognition receptor in the SKP1-Cullin1-F-box protein (SCF) E3 Ub ligase complex. FBXW2 suppresses proliferation and invasion of lung cancer cells by targeting S phase kinase-associated protein 2 (SKP2) and β-catenin (Fig. 2). FBXW2 is downregulated and negatively correlated with β-catenin in lymph-node metastasis [8, 9]. Meanwhile, FBXW2 is a novel substrate of β-transducin repeat-containing protein 1 (β-TrCP1). Following growth factor stimulation, β-TrCP1 targets FBXW2 for ubiquitination degradation. The accumulation of SKP2 subsequently leads to the degradation of tumor suppressors and apoptosis-inducing substrates, such as p21, p27, p130, and FOXO1, to promote tumor cell proliferation, growth, and survival [8]. The β-TrCP-FBXW2-SKP2 signaling cascade forms the oncogene (β-TrCP1)-tumor suppressor gene (FBXW2)-oncogene (SKP2) axis that regulates the growth and survival of lung cancer cells via targeting each other for degradation, which is a process of crucial crosstalk among F-box proteins. In hepatocellular carcinoma (HCC), FBXW2 targets transforming growth factor-β-activated kinase 1 (TAK1) for K48-linked polyubiquitination and degradation to inhibit cancer progression [10] (Fig. 2). Clinically, FBXW2 levels could be a significant indicator of the prognosis and survival of patients with cancer.

F-box and WD repeat domain-containing 7 (FBW7)

FBW7 is a substrate recognition receptor of the SCFFB7 E3 Ub ligase complex. It functions as a tumor suppressor and mediates ubiquitination-induced degradation of various oncogenic proteins, including c-MYC, NOTCH, c-JUN, and cyclin E [11]. In gastric cancer, transcription activator Brg1 (Brg1) binds to the promoter of Snail, which subsequently promotes EMT and metastasis. Meanwhile, Brg1 is a Ub substrate of the SCFFB7 E3 ligase complex. Casein kinase 1 (CK1)β-mediated phosphorylation at Ser31/Ser35 sites of Brg1 strengthens FBW7-binding capacity, thus accelerating the ubiquitination of Brg1[12] (Fig. 2). Methylation induces epigenetic silencing of the FBW7 gene. Decitabine (DAC) epigenetically activates FBW7 expression via its demethylation. DAC-activated FBW7 promotes myeloid leukemia cell differentiation protein Mcl-1 ubiquitination and degradation to suppress lung cancer growth [13]. YTH domain-containing family protein 2 (YTHDF2) is the N6-methyladenosine (m6A) reader protein and promotes the decay of the m6A-modified mRNAs. FBW7 can degrade YTHDF2 by ubiquitination and suppress the propagation of ovarian cancer [14] (Fig. 2).

Putative E3 Ub-protein ligase UBR7 (UBR7)

UBR7 belongs to the Ub-protein ligase E3 component N-recognin (UBR) family and has a unique plant homeodomain (PHD) finger [15]. PHD fingers are central “readers” of histone post-translational modifications [16]. UBR7-PHD finger monoubiquitinates histone H2B in triple-negative breast tumors at lysine 120 (H2BK120Ub). H2BK120Ub enhances cadherin-4 (CDH4) transcription activity and expression level [15]. CDH4 overexpression notably suppresses EMT and reduces cellular proliferation, migration, and invasion [15] (Fig. 2). Meanwhile, CDH4 can regulate the Wnt/β-catenin signaling pathway. It alters the nuclear localization of β-catenin to the cytoplasm, which downregulates β-catenin target genes, including AXIN2, G1/S-specific cyclin-D1, C-MYC, COX2, and MMP7, to suppress tumor metastasis [17, 18].

Parkin

Notably, as an E3 Ub ligase, Parkin can degrade substrate proteins associated with Parkinson’s Disease (PD) [19]. Meanwhile, Parkin acts as a tumor
suppressor, and its expression is downregulated in various tumors [20]. Parkin is an E3 Ub ligase for hypoxia-inducible factor 1α (HIF-1α) and can ubiquitinate HIF-1α at lysine 477 (K477), inhibit HIF-1α transcriptional activity, and induce its degradation to suppress breast cancer cells invasion and metastasis [21, 22]. Parkin regulates HIF-1α in a Von Hippel-Lindau-independent manner, unveiling an additional layer of regulation for HIF-1α in cells. Phosphoglycerate dehydrogenase (PHGDH) is the first rate-limiting enzyme of serine synthesis. PHGDH overexpression activates serine synthesis to promote cancer progression. Parkin expression is inversely correlated with PHGDH expression in breast and lung cancer. Parkin interacts with PHGDH and ubiquitimates PHGDH at lysine 330, leading to PHGDH degradation to suppress serine synthesis [23]. In intrahepatic cholangiocarcinoma (ICC), Parkin targets pyruvate kinase PKM2 for ubiquitination degradation to suppress migration and proliferation [24] (Fig. 2).

Figure 1. A brief overview of the ubiquitination pathway. Ubiquitination is catalyzed by a three-enzyme cascade composed of the E1 Ub-activating enzyme, the E2 Ub-conjugating enzyme, and the E3 Ub ligase. The E3 ligase selectively recognizes substrate proteins by forming an iso-peptide bond and recruits the Ub-E2 complex to catalyze the transfer of Ub to the substrate from E2. Elongation and distinct polyubiquitin chains are involved in protein degradation, signal transduction, and transcriptional activity. Deubiquitinases remove Ub moieties from substrate proteins with high specificity and reverse Ub signals to maintain cellular dynamic ubiquitination.

Figure 2. Different E3 Ub ligases regulate tumor metastasis. FBXW2 targets SKP2, β-catenin, and TAK1, FBW7 targets Brp1, Mcl-1, and YTHDF2, and Parkin targets HIF-1α, PHGDH, and PKM2 for ubiquitination degradation to suppress tumor proliferation and metastasis, respectively. UBR7 monoubiquitinates histone H2B to suppress EMT and nuclear β-catenin. UBE3C targets AHI1 and AXIN1 for ubiquitination-induced degradation. TRIM65 ubiquitinates ARHGAP35, FBXO22 ubiquitinates nuclear PTEN and p21 to enhance cancer cell migration, respectively. FBXO22 mediates Lys-63-linked LKB1 ubiquitination. FBXO22 upregulates HIF-1α and VEGFA to promote tumor proliferation and metastasis.
E3 Ub ligases promoting metastasis

**Ub-protein ligase E3C (UBE3C)**

UBE3C belongs to the HECT family of E3 Ub ligases. It functions as a tumor promoter and is aberrantly expressed in breast cancer [25], hepatocellular carcinoma [26], and renal cell carcinoma [27]. In non-small cell lung cancer (NSCLC) tissues, UBE3C maintains cancer stemness by ubiquitinating and promoting neuroblast differentiation-associated protein AHNAK (AHNAK) degradation [28]. AHNAK is a cofactor that assists P53 binding to stemness-related gene promoters. UBE3C-mediated degradation of AHNAK abrogates P53-AHNAK complex-mediated inhibition of gene expression, which enhances lung cancer cell stemness and NSCLC growth and metastasis [28, 29]. UBE3C targets AXIN1 for ubiquitination degradation to activate β-catenin signaling in gastric cancer [30] (Fig. 2).

**Tripartite motif-containing protein 65 (TRIM65)**

Tumor metastasis involves the reorganization of the cytoskeleton, whose activities are controlled by GTPases [31]. When bound to guanosine diphosphate (GDP), GTPases are inactivated, which is regulated by GTPase-activating protein (GAP) [32]. Rho A belongs to the Rho family of GTPases and regulates the cytoskeleton. Rho GTPase-activating protein 35 (ARHGAP35), a Rho GAP, regulates polarized cell migration and inhibits Rho GTPase. In colorectal cancer (CRC), E3 Ub ligase TRIM65 ubiquitinates and degrades ARHGAP35, which leads to subsequent elevated Rho GTPase activity and cytoskeleton remodeling [33] (Fig. 2). The TRIM65-ARHGAP35-Rho A axis enhances cancer cell migration by modulating the actin cytoskeleton.

**F-box only protein 22 (FBXO22)**

FBXO22, one of the F-box-only proteins, is the substrate-recognizing subunit of the SCF E3 Ub ligase complex [34]. FBXO22 ubiquitinates nuclear PTKTEN at lysine 221 (K221). Nuclear PTKTEN exerts potent tumor inhibition capacity. In CRC tissues, FBXO22 overexpression contributes to the downregulation of nuclear PTKTEN to promote tumorigenesis, which is reversed by the mutation of K221 [35]. FBXO22 is upregulated and negatively correlated with p21 in HCC. FBXO22 functions as an oncogene by mediating the ubiquitination and degradation of p21 to promote HCC pathogenesis and progression [36]. FBXO22 mediates Lys-63-linked liver kinase B1 (LKB1) polyubiquitination and inhibits LKB1-AMPK-mTOR signaling in lung adenocarcinoma [37]. FBXO22 promotes melanoma angiogenesis and migration of tumor cells via upregulating HIF-1α and vascular endothelial growth factor A (VEGFA) [38] (Fig. 2).

**DUBs**

DUBs can reverse ubiquitination by cleaving the isopeptide bond between the Ub and the substrate. Currently, over 100 DUBs have been identified and can be divided into six subclasses: i) Ub-specific proteases (USPs); ii) ovarian tumor proteases (OTUs); iii) Ub C-terminal hydrolases (UCHs); iv) Machado-Joseph disease proteases; v) JAB1/MPN/Mov34 metalloenzymes; and vi) monocyte chemotactic protein-induced protein [39]. DUBs act as tumor suppressors or oncogenes and play essential roles in regulating various types of tumors (Table 1). DUBs have emerged as promising therapeutic targets in cancer.

**Table 1. A brief overview of different DUBs in various cancers**

| DUBs      | Biological effect | Brief biological mechanism                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Involvement in cancer                                                                                                                                                                                                                          | Refs |
|-----------|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| USP1      | Oncogene          | Phosphorylated USP1 (via ATM/ATR) deubiquititates and stabilizes Snail. USP1 deubiquititates KPNAA2 and enhances pro-metastatic genes expression. USP1 deubiquititates and increases TAZ protein stability. USP1 deubiquititates and stabilizes ribosomal protein S16 (RPS16).                                                                                                                                | USP1 induces platinum resistance, cancer cell stemness, and metastatic dissemination in ovarian cancer. The intervention of USP1 via pimozone or ML323 suppresses metastasis.                                                                                   | [66] |
| USP2a     | Oncogene          | On TGF-β stimulation, USP2a deubiquititates TGFBR1 (K33-linked ubiquitin chain), recruiting SMAD2. TGFBR2 subsequently phosphorylates USP2a, facilitating SMAD2 into the cytoplasm.                                                                                                                                                                                                                                                   | Loss of USP1 reduces TAZ to inhibit cell proliferation and migration, and USP1 is a potential therapeutic target in triple-negative breast cancer (TNBC). USP1-mediated RPS16 stabilization promotes cell proliferation and metastasis in hepatocellular carcinoma (HCC). It is associated with trans-activating EMT genes to promote metastasis in lung adenocarcinomas. | [69] |
| USP3      | Oncogene          | USP3 deubiquititates and upregulates SUZ12 protein expression.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | USP2a is highly upregulated and promotes hepatocellular carcinoma (HCC) cell progression. USP3 promotes TGF-β1-induced EMT and cell migration in gastric cancer. USP4 enhances cancer cell stemness which mediates tumor development and metastasis in lung cancer and breast cancer. | [70] |
| USP4      | Oncogene          | USP4 deubiquititates and stabilizes Twist1 protein. USP4 constituting the PAK5-DNPEP-USP4 axis. Aberrant PAK5 phosphorylates DNPEP, which preferentially                                                                                                                                                                                                                                                                                                                                                              | USP4 elicits cancer cell proliferation, invasion, and metastasis in breast cancer.                                                                                                                                                                                                                           | [71] |

Current position of DUBs in cancer research.

https://www.ijbs.com
| DUBs | Biological effect | Brief biological mechanism | Involvement in cancer | Refs |
|------|-------------------|---------------------------|----------------------|------|
| USP5 | Oncogene          | USP5 deubiquinates and stabilizes SLUG. USP5 promotes EMT, tumor growth, and metastasis, rescuing by Fornonemotargeting USPs in hepatocellular carcinoma (HCC). USP5 is overexpressed in non-small cell lung cancer to promote EMT, invasion, and metastasis. | USP5 promotes EMT, tumor growth, and metastasis, rescuing by Fornonemotargeting USPs in hepatocellular carcinoma (HCC). USP5 is overexpressed in non-small cell lung cancer to promote EMT, invasion, and metastasis. | [77] |
| USP6 | Oncogene          | USP6 promotes invasion and metastasis, and acts as an efficient prognostic biomarker. Inhibition of USP7 can arrest bone marrow-resident tumor cells (BMRTC) in BM and decrease metastasis. USP7 could be a therapeutic target in melanoma. | USP6 is highly overexpressed in colon cancer. | [79] |
| USP7 (HAUSP) | Oncogene | USP7 promotes the circulation of tumor cells (CTCs) to reside in the bone marrow. K63-polyubiquitinated HAUSP deubiquitinates and stabilizes HIF-1α, and causes CBP-mediated H3K56 acetylation to regulate HIF-1α target gene promoters. USP7 promotes proliferation and invasion. Under hypoxia, Er3 ligase HectH9 is required for K63-polyubiquitinated HAUSP to promote EMT and metastasis in lung cancer. | Overexpressed USP7 represents a worse overall survival and acts as an independent prognostic indicator in epithelial ovarian cancer (EOC) and oral squamous cell carcinoma (OSCC). | [80, 81] |
| USP8 | Oncogene          | USP8 overexpression activates the PI3K/AKT signaling pathway. USP8 activates the Wnt/β-catenin signaling pathway. USP8 increases the relative abundance of myeloid cells vs. cytotoxic T cell and inhibits cell proliferation and DNA damage and suppresses cell migration and invasion in melanoma. USP8 suppresses apoptosis and promotes proliferation, invasion, and metastasis in cholangiocarcinoma. | USP8 is a protective factor and prognosticates better clinical outcomes. | [82, 83] |
| USP9X (Tumor suppressor gene) | Oncogene | USP9X activates EMT. USP9X overexpression promotes invasion and migration, and inhibits apoptosis in pancreatic ductal adenocarcinoma (PDAC). USP9X enhances TGFβ-induced EMT to promote breast cancer metastasis. | USP9X overexpression promotes invasion and migration, and inhibits apoptosis in pancreatic ductal adenocarcinoma (PDAC). | [88, 89] |
| USP10 | Oncogene          | USP10 deubiquitinates Smad4 (K48) and activates TGF-β. USP10 knockdown suppresses Smad4 and metastasis in hepatocellular carcinoma. USP10 is highly expressed and stabilizes NLRP7 to promote cell proliferation and metastasis in colorectal cancer. | USP10 siRNA and Spautin1 inhibitor can downregulate USP10 to suppress Smad4 and metastasis in hepatocellular carcinoma. | [90, 91] |
| USP11 | Oncogene          | USP11 deubiquitinates and stabilizes PTEN to activate the ERK/MAPK pathway. USP11 deubiquitinates and stabilizes nuclear factor (NFκB) via MAPK activation. USP11 is overexpressed and promotes metastasis in colorectal cancer. | USP11 is an independent prognostic predictor. | [92-95] |
| USP12 | Oncogene          | USP12 deubiquitinates and stabilizes midkine (MDK). USP12 inhibits Lidoicaine (Lido) suppresses proliferation and migration while aggravating hepatocellular carcinoma cell apoptosis. | USP11 antagonizes with TRIM32 to stabilize ARID1A and to suppress proliferation and metastasis in squamous cell carcinomas (SCCs). PTEN inhibits the PI3K/AKT-mediated phosphorylation of FOXO to increase its nuclear localization and to enhance USP11 transcription. The PI3K/PIK/AKT-FIXUSP11 regulatory feedforward loop regulates the tumor-suppressive activity of PTEN. | [96, 97] |
| USP14 | Oncogene          | USP14 inhibits Lidoicaine (Lido) suppresses proliferation and migration while aggravating hepatocellular carcinoma cell apoptosis. | USP14 inhibits Lidoicaine (Lido) suppresses proliferation and migration while aggravating hepatocellular carcinoma cell apoptosis. | [98] |
| USP15 | Oncogene          | USP15 overexpression promotes proliferation and migration and prevents apoptosis. USP15 promotes β-catenin nuclear translocation and activates the Wnt/β-catenin pathway. High USP15 expression indicates a worse prognosis, and USP15 could be a therapeutic target in hepatocellular carcinoma. USP15 is upregulated and promotes EMT, cell proliferation, and metastasis. | USP15 overexpression promotes proliferation and prevents apoptosis. USP15 promotes β-catenin nuclear translocation and activates the Wnt/β-catenin pathway. High USP15 expression indicates a worse prognosis, and USP15 could be a therapeutic target in hepatocellular carcinoma. USP15 is upregulated and promotes EMT, cell proliferation, and metastasis. | [99] |
| USP18 | Oncogene          | USP18 deubiquitinates ZEB1. USP18 is overexpressed and induces ZEB1-mediated EMT to promote metastasis in esophageal squamous cell carcinomas (ESCC). | USP18 is overexpressed and induces ZEB1-mediated EMT to promote metastasis in esophageal squamous cell carcinomas (ESCC). | [100] |
| USP20 | Oncogene          | USP20 deubiquitinates β-catenin. USP20 highly expresses and regulates the Wnt/β-catenin pathway to potentiate tumorigenesis in colon cancer. USP20 upregulates and promotes EMT and metastasis in bladder cancer. | USP20 highly expresses and regulates the Wnt/β-catenin pathway to potentiate tumorigenesis in colon cancer. USP20 upregulates and promotes EMT and metastasis in bladder cancer. | [101] |
| USP21 | Oncogene          | USP21 deubiquitinates EZH2. USP21 deubiquitinates Fos-related-antigen-1 (Fra-1) and enhances AP-1 target gene expression. USP21 overexpresses and promotes FRA1-dependent metastasis in colorectal cancer. | USP21 deubiquitinates EZH2. USP21 deubiquitinates Fos-related-antigen-1 (Fra-1) and enhances AP-1 target gene expression. USP21 overexpresses and promotes FRA1-dependent metastasis in colorectal cancer. | [102] |
| USP22 | Oncogene          | USP22 activates AP4 transcription to induce EMT. USP22 stabilizes BM1 protein to maintain cancer stemness. High USP22 enhances angiogenesis, metastasis, and recurrence. USP22 increases the relative abundance of myeloid cells vs. cytotoxic T cells via its deubiquitinase activity. USP22 promotes gastric cancer progression by modulating FOXO1 and the YAP signaling pathways via c-Myc/NAMPT/SIRT1. USP22 overexpressed, and its depletion suppresses invasion and metastasis in gastric cancer. | USP22 overexpressed and facilitates proliferation in gastric cancer. USP22 overexpressed and facilitates proliferation in gastric cancer. USP22 overexpressed and facilitates proliferation in gastric cancer. USP22 overexpressed and promotes invasion and metastasis in gastric cancer. | [103-111] |
| TSG  | Oncogene          | USP22 decreases mTOR activity. USP22 deficiency activates mTOR and tumorigenesis, reversed by mTOR. | USP22 deficiency activates mTOR and tumorigenesis, reversed by mTOR. | [112] |
| DUBs | Biological effect | Brief biological mechanism | Involvement in cancer | Refs |
|------|-------------------|---------------------------|----------------------|------|
| USP25 | Oncogene | miRNA 20c reduces the USP25 gene mRNA and protein levels to inhibit invasion and migration. | USP25 protein and mRNA levels are highly expressed in non-small cell lung cancer. | [113] |
| USP26 | Oncogene | USP26 deubiquitinites and stabilizes Snail. | USP26 is highly expressed in esophageal squamous cell carcinoma (ESCC). | [114] |
| USP28 | Oncogene | USP28 stabilizes lysine specific demethylase1. USP28 antagonizes GSK3β-Fbw7-dependent HIF-1α ubiquitination degradation to affect HIF-1α-dependent angiogenesis and carcinogenesis. | USP28 is overexpressed in gastric cancer. | [115, 116] |
| USP29 | Oncogene | USP29 interacts simultaneously with Snail and SCPT1 to stabilize Snail via deubiquitination and dephosphorylation. | TNP5, TG5, and Hypoxia can induce USP29 to promote gastric cancer cell migration. | [117] |
| USP33 | Oncogene | USP33 deubiquitinites specificity protein 1 (SPT1) to upregulate c-met. | USP33 is overexpressed and is a prognostic biomarker and therapeutic target in hepatocellular carcinoma. | [118, 119] |
| TSG | Oncogene | TSG3 can deubiquitinate and stabilize Robo1 to inhibit EMT and cell migration in a Slt-RhoB pathway-dependent manner. | USP33 expression is downregulated and it is an independent prognostic marker in colorectal cancer and gastric cancer. | [120, 121] |
| USP37 | Oncogene | USP37 deubiquitinites Snail. USP37 stabilizes the hedgehog (Hh) pathway component GLI-1. USP37 binds and deubiquitinitates Snail. | Upregulated expression of USP37 promotes lung cancer cell migration. USP37 can regulate the stemness, cell invasion, cisplatin sensitivity, and EMT via the Hh pathway in breast cancer. | [122-124] |
| USP43 | Oncogene | USP43 physically binds to the chromatin remodeling NuRD complex and catalyzes H2B120 deubiquitination to repress the EGFR gene. | USP43 is overexpressed in esophageal squamous cell carcinoma (ESCC). | [52] |
| USP44 | Oncogene | USP44 deubiquitinites EZH2, a histone H3 lysine 27 methyltransferase. USP44 expression in breast cancer stem cells (CSC) contributes to the formation of vasculogenic mimicry (VM) to promote transendothelial migration. USP44 knockdown decreases the EZH2 protein level and inhibits prostate cancer cells’ tumorigenesis and cancer stem cell-like behaviors. USP44 silencing ablates VM and USP44/CSC subclones act as an independent prognostic biomarker in breast cancer. | USP44 is correlated to a poor prognosis for breast cancer patients. | [125, 126] |
| USP46 | Oncogene | USP46 deubiquitinites ENO1 and promotes EMT. | The expression of USP46 is elevated, and silencing USP46 can promote Snail degradation and attenuate EMT in colorectal cancer. | [127] |
| USP47 | Oncogene | USP47 deubiquitinites and stabilizes Snail to induce EMT. USP47, as a novel target of Sox9, mediates hypoxia-induced EMT via deubiquitinating Snail. USP47 abrogates the SMURF2-mediated ubiquitination of special AT-rich sequence-binding protein 1 (SATB1) to promote colon cancer cell proliferation and metastasis. USP47 deubiquitinates EZH2, a histone H3 lysine 27 methyltransferase. | USP47 is overexpressed and is a potential prognostic and therapeutic target in NSCLC. USP47 depletion sensitizes colon cancer cells to 5-FU treatment-induced apoptosis. | [128-130] |
| USP48 | Oncogene | USP48 physically binds to the chromatin remodeling NuRD complex and catalyzes H2B120 deubiquitination to repress the EGFR gene. | USP54 is overexpressed in colorectal carcinoma and is a promising therapeutic target. | [131] |
| USP51 | Oncogene | USP51 increases FAT4 protein level and is imperative for FAT4’s function. | USP51 suppression contributes to the inhibition of FAT4 and promotes proliferation and invasion of endometrial cancer (EC). | [132-134] |
| OTUB1 | Oncogene | OTUB1 is highly expressed in esophageal squamous cell carcinoma (ESCC), and higher expression of OTUB1 predicts poor prognosis. | USP51 is correlated to a poor prognosis for breast cancer patients. The expression of USP51 is correlated to a poor prognosis for breast cancer patients. | [135, 136, 137] |
| OTUB2 | Oncogene | OTUB2 can deubiquitinate U2AF2 and activate the AKT/mTOR pathway. | OTUB2 can deubiquitinate U2AF2 and activate the AKT/mTOR pathway. OTUB2 can deubiquitinate and activate YAP/TAZ. | [138, 139] |
| OTUD1 | TSG | OTUD1 deubiquinites K48-linked and K33-linked SMAD7 to enhance SMURF2 binding to suppress TGFβ. High-level OTUD1 inhibits TGFβ-induced cancer stemness and metastasis in breast cancer. | Reduction of OTUD3 causes decreased PTEN abundance and correlates with breast cancer progression. | [139] |
| OTUD2 | Oncogene | OTUD2 couples pVHL to form the CBC^{cyc} complex to decrease its ubiquitination degradation, thereby attenuating HIF-1α. | OTUD26 is positively correlated with pVHL, but negatively with HIF-1α and vascular endothelial growth factor in hepatocellular carcinoma. | [140] |
| OUTD6B | TSG | OUTD6B promotes proliferation and metastasis via the Akt/VEGFR signal pathway. | OUTD6B is highly expressed in lung squamous carcinoma and adenoscarcinoma, and correlates with a worse prognosis, and may be an independent predictive indicator. | [141] |
| BAP1 | Oncogene | BAP1 deubiquitinites transcription factor KLF3. | BAP1 knockdown inhibits breast cancer tumorigenicity and lung metastasis, and BAP1 could be a therapeutic target. | [142] |
| CYLD | TSG | CYLD regulates genes involved in proliferation, migration, and angiogenesis. | CYLD-deficiency enhances melanoma progression. | [143] |
DUBs inhibiting metastasis

Ub carboxyl-terminal hydrolase BAP1 (BAP1)

BAP1 belongs to the UCH domain-containing proteins, and it can physically bind to and deubiquitinate PTEN to stabilize PTEN protein. Downregulated BAP1 leads to the decrease of PTEN protein levels and the activation of the Akt signaling pathway, therefore promoting malignant transformation and metastasis in prostate cancer. Clinically, low BAP1 expression is positively correlated with aggressive prostate tumor proliferation and lymphatic metastasis [40]. In ICC, BAP1 inhibits ERK1/2 and JNK/c-Jun pathways [41]. Moreover, BAP1 mediates the metabolic regulation of ferroptosis and tumor suppression. BAP1 reduces histone 2A ubiquitination (H2AUb) on the cystine/glutamate transporter (SLC7A11) promoter and represses SLC7A11 expression in a deubiquitination-dependent manner [42]. The loss of cystine transport mediated by SLC7A11 induces ferroptosis to inhibit tumor development and metastasis [43] (Fig. 3). In summary, as a major tumor suppressor, mutated BAP1 is associated with numerous human malignancies, which is defined as “BAPI cancer syndrome” [44].

OTU domain-containing protein 1 (OTUD1)

In the TGF-β signaling pathway, SMAD7 recruits E3 ligase SMURF2 to TGF-β type I receptor (TβRI) [45]. However, E3 Ub-protein ligases RNF12 and Itchy homolog can degrade SMAD7 to antagonize its suppression [46, 47]. In breast cancer, OTUD1 can selectively eliminate the K48-linked Ub chain from SMAD7 to stabilize it (Fig. 3). Moreover, OTUD1 can cleave the K33-linked Ub chain on the lysine 220 site and unveil the PY motif of SMAD7 [48]. Moreover, OTUD1 can cleave the K48-linked Ub chain from the WW domain of SMURF2 to degrade TβRI via ubiquitination [45, 49]. In summary, OTUD1 suppresses the TGF-β-induced metastasis by exerting dual effects on SMAD7.

Ub carboxyl-terminal hydrolase 43 (USP43)

The EGFR/Pi3K/AKT pathway is aberrantly activated in various cancers [50]. PTEN can negatively regulate AKT kinase activity [51]. In addition, another molecular regulatory mechanism exists. Nuclear USP43 is physically associated with the nucleosome remodeling and deacetylase (NuRD) complex. The USP43-NuRD complex coordinately catalyzes H2BK120 deubiquitination to suppress downstream EGFR [52] (Fig. 3). Simultaneously, activated AKT can phosphorylate cytoplasmic USP43 on Ser29, phosphorylated USP43 is detained in the cytoplasm, reduced nuclear USP43 and accumulated EGFR potentiate the EGFR/Pi3K/AKT pathway to promote breast cell proliferation and invasion [52]. USP43 is a hub of the USP43-NuRD complex, the reciprocally inhibitory loop between the USP43-NuRD complex and the EGFR/Pi3K/AKT pathway synergistically modulates breast carcinogenesis. The ratio of nuclear/cytoplasmic USP43 is a worthy prognostic

---

**DUBs** | **Biological effect** | **Brief biological mechanism** | **Involvement in cancer** | **Refs**
--- | --- | --- | --- | ---
UCHL1 | Oncogene | UCHL1 can reverse the K63 ubiquitination of c-Jun and c-Fos to repress the JNK/API pathway. Small1 inhibits CYLD to promote BCL-3 nuclear translocation, activating cycling D1 and N-cadherin. | CYLD mutant enhances squamous cell carcinoma growth and migration in an API-dependent manner. Uregulation of CYLD expression can repress proliferation and invasion in melanoma. UCHL1 is overexpressed, and knockdown can induce MET in metastatic prostate cancer. AKT negative mutant and silencing UCHL1 suppress invasion and metastasis in non-small cell lung cancer. ERK inhibitor U0126 can block multidrug resistance and invasion in UCHL1-overexpressed breast cancer cells. UCHL1 is overexpressed in breast and lung cancer. It may be a prognostic marker and therapeutic target. UCHL1 might serve as a potential diagnostic and prognosis biomarker for RCC patients. | [51-156] |
UCHL5 | Oncogene | UCHL5 can activate the Wnt/β-catenin pathway and upregulate β-catenin. | UCHL5 is overexpressed, and promotes tumorigenesis and growth in endometrial cancer (EC), which can be abrogated by the Wnt/β-catenin pathway inhibitor XAV939. | [157] |
COPS5 | Oncogene | COPS5 deubiquitinates HK2 and attenuates its degradation to regulate glycolysis. | COPS5 deubiquitinates and stabilizes ZEB1. | [158, 159] |
COPS6 | Oncogene | COPS6 increases CHIP self-ubiquitination to elevate EGFR stability. | COPS6 is overexpressed and the CSN6-CHIP-EGFR axis could be a therapeutic target in glioblastoma. COPS6 and CTSL are overexpressed and indicate aggressive cervical mitor pathway. | [160, 161] |
ATXN3 | Oncogene | ATXN3 deubiquitinates KLF4. | High ATXN3 and KLF4 expression are associated with a poor prognosis in breast cancer patients. | [162] |

https://www.ijbs.com
**DUBs promoting metastasis**

**USP7**

USP7 can coordinate with histone-lysine N-methyltransferase EZH2 (EZH2)-catalyzed methylation to remove ubiquitination and enhance FOXA1 protein stability, promoting prostate cancer growth [53]. Moreover, USP7 can stabilize EZH2 via deubiquitination [54] (Fig. 3). USP7 is upregulated in M2 macrophages. USP7 inhibition can induce the polarization of tumor-associated macrophages from M2 into M1 by activating the P38 MAPK pathway and upregulating the expression of programmed cell death 1 ligand 1 (PD-L1) in the tumor microenvironment [55]. Therefore, USP7 blockade combined with anti-PD-1 immunotherapy exert an inhibitory effect on tumors in lung cancer.

**SUMOylated-Ub thioesterase OTUB2 (OTUB2)**

Transcriptional coactivator YAP1 (YAP) and tafazzin (TAZ) are generally downregulated by the canonical Hippo pathway [56]. However, YAP and TAZ are hyperactivated and induce tumor proliferation and metastasis, while the Hippo pathway is still active in multiple malignancies, including breast cancer [57, 58]. DUB OTUB2 mediates the activation of YAP and TAZ in a Hippo-independent manner (Fig. 3). Mechanistically, OTUB2 is poly-SUMOylated at lysine 233 (K233), SUMOylated-OTUB2 can subsequently bind YAP/TAZ through SUMO-interacting motif in YAP and TAZ [58]. OTUB2 deubiquitiinates and activates YAP and TAZ, and accumulated YAP and TAZ translocate into the nucleus in which they interact with TEA domain family transcription factors and transcriptionally activate genes to potentiate cell proliferation and metastasis [59, 60]. Meanwhile, activated EGF-RAS signaling strengthens OTUB2 SUMOylation and elevates YAP/TAZ protein levels to promote cancer stemness and metastasis [58, 61]. In summary, the novel SUMOylated-OTUB2-mediated regulatory mechanism expands the complexity of YAP/TAZ beyond the Hippo pathway. OTUB2 may be a potential drug target to suppress cancer progression for patients harboring RAS mutations.

**Dub3**

Snail1 is a critical EMT-driving transcription factor and confers tumor metastatic and cancer stem cell-like properties [62]. The E3 ligases β-TrCP1 and F-box/LRR-repeat protein 14 (FBXL14) can degrade Snail1 via ubiquitination [63]. In breast cancer, Dub3 accounts for Snail1 stabilization, and inflammatory cytokine IL-6 can increase the expression of Dub3. Meanwhile, Dub3 also inhibits the activity of β-TrCP1 and FBXL14 to block Snail1 ubiquitination [64] (Fig. 3). Overall, Dub3 senses inflammatory stimulation and converts it into Snail1 stabilization.

---

**Figure 3. Different DUBs regulate tumorigenesis.** BAP1 can deubiquitinate PTEN and reduce H2AUb on the SLC7A11 promoter to inhibit tumor development and metastasis. OTUD1 can eliminate the K48-linked Ub chain from SMAD7. The USP43-NuRD complex catalyzes H2BK120 deubiquitination to suppress downstream EGFR. USP7 can stabilize EZH2 and FOXA1 via deubiquitination to promote tumor growth. USP7 upregulates PD-L1 expression in the tumor microenvironment. SUMOylated-OTUB2 deubiquitiinates YAP/TAZ to potentiate tumor cell proliferation and metastasis in a Hippo-independent manner. Dub3 can stabilize Snail1 via deubiquitination and inhibiting β-TrCP1 and FBXL14-mediated ubiquitination degradation.
Conclusion

Although this brief review only scratches the surface of ubiquitination and deubiquitination in cancer, it highlights the significance of E3s and DUBs in a range of processes involved in tumor progression. Ubiquitination components are potential therapeutic targets for cancer treatment [65]. However, several issues remain obstacles for targeted therapy. DUBs share similar structural characteristics among family members, and ubiquitination involves substantial conformational changes. We still endeavor to deal with the challenges ahead, such as defining novel E3s, DUBs, and targeted substrates, investigating whether there exists unknown crosstalk among distinct E3s or DUBs, and decoding the unknown pathways linking ubiquitination with other cellular physiological mechanisms. Several valuable E3s or DUBs are promising clinical prognostic indexes and drug targets. Proteolysis Targeting Chimeras (PROTACs) exploit the intracellular Ub-proteasome system to degrade target proteins [66], selectively. In tumor xenografts, small-molecule PROTACs can significantly attenuate tumor progression [67].

This review provides a glimpse into the importance and extensiveness of ubiquitination component-mediated tumor invasion and metastasis, which represents a worthy research prospect.

Abbreviations

Ub: ubiquitin; DUBs: deubiquitinas; SKP2: S phase kinase-associated protein 2; FBXW2: F-box and WD-repeat domain-containing 2; TAK1: transforming growth factor-β-activated kinase 1; β-TrCP1: β-transducin repeat-containing protein 1; FBW7: F-box and WD repeat domain-containing 7; Brg1: transcription activator Brg1; Mcl-1: induced myeloid leukemia cell differentiation protein Mcl-1; YTHDF2: YTH domain-containing family protein 2; EMT: epithelial-mesenchymal transition; CK1: casein kinase 1; UBRT7: putative E3 Ub-protein ligase UBR7; CD4H: cadherin-4; HIF-1α: hypoxia-inducible factor 1α; PHGDH: phosphoglycerate dehydrogenase; PTK2: Protein tyrosine kinase PTK2; UBE3C: Ub-protein ligase E3C; AHNAK: neuroblast differentiation-associated protein AHNAK; TRIM65: tripartite motif-containing protein 65; Rho GTPase-activating protein 35; FBXO22: F-box only protein 22; LKB1: liver kinase B1; VEGFA: vascular endothelial growth factor A; BAP1: Ub carboxyl-terminal hydrolase BAP1; H2AUB: histone H2A ubiquitination; SLC7A11: cysteine/glutamate transporter; SMURF2: E3 Ub-protein ligase SMURF2; TJP1: TGF-β type I receptor; OTUD1: OTU domain-containing protein 1; USP43: Ub carboxyl-terminal hydrolase 43; NuRD: nucleosome remodeling and deacetylase; H2BK120: histone H2B at lysine 120; USP: Ub-specific protease; EZH2: histone-lysine N-methyltransferase EZH2; PD-L1: programmed cell death 1 ligand 1; OTUB2: Ub thioesterase OTUB2; YAP: transcriptional coactivator YAP1; TAZ: tafazzin; FBXL14: F-box/LRR-repeat protein 14.

Acknowledgments

We apologize to colleagues whose work was not cited due to space limitations. This study was supported by China’s National Natural Science Foundation (No.81972837).

Competing Interests

The authors have declared that no competing interest exists.

References

1. Swatek KN, Komarde D. Ubiquitin modifications. Cell Res. 2016; 26: 399-422.
2. Zheng N, Shabek N. Ubiquitin Ligation: Structure, Function, and Regulation. Annual review of biochemistry. 2017; 86: 129-57.
3. Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the human deubiquitinating enzyme interaction landscape. Cell. 2009; 138: 389-403.
4. Clague MJ, Uбе S, Komander D. Breaking the chains: deubiquitylating enzyme specificity begets function. Nature reviews Molecular cell biology. 2019; 20: 338-52.
5. Decoding cancer metastasis. Nat Cell Biol. 2018; 20: 859.
6. Massagué J, Obenauf AC. Metastasis: molecular mechanisms. Nature. 2016; 529: 298-306.
7. Pastushenko I, Blanpain C. EMT Transition States during Tumor Progression and Metastasis. Trends in cell biology. 2019; 29: 212-26.
8. Xu J, Zhou W, Yang F, Chen G, Li H, Zhao Y, et al. The β-TrCP-FBW2-SKP2 axis regulates lung cancer cell growth with FBW2 acting as a tumour suppressor. Nat Commun. 2017; 8: 14002.
9. Yang F, Xu J, Li H, Tan M, Xiong X, Sun Y. FBW2 suppresses migration and invasion of lung cancer cells via promoting β-catenin ubiquitination and degradation. Nat Commun. 2019; 10: 1382.
10. Xia S, Ji L, Tao L, Pan Y, Lin Z, Wan Z, et al. TAK1 Is A Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance. Cellular and molecular gastroenterology and hepatology. 2021; 12: 1121-43.
11. Davis RJ, Wekker M, Chroman BE. Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities. Cancer cell. 2014; 26: 455-64.
12. Huang LY, Zhao J, Chen H, Wan L, Inuzuka H, Guo J, et al. SCL/FBW7-mediated degradation of β-catenin suppresses gastric cancer metastasis. Nat Commun. 2018; 9: 3569.
13. Kim MJ, Chen G, Sica GL, Deng X. Epigenetic modulation of FBW7/Mcl-1 pathway for lung cancer therapy. Cancer biology & therapy. 2021; 22: 55-65.
14. Xu F, Li J, Ni M, Cheng J, Zhao H, Wang S, et al. FBW7 suppresses ovarian cancer development by targeting the N(6)-methyladenosine binding protein YTHDF2. Molecular cancer. 2021; 20: 45.
15. Adhikary S, Chakravarti D, Terranova C, Sengupta I, Malitouhetti M, Danzigna A, et al. Atypical plant homeodomain of UBR7 functions as an H2BK120Ub ligase and breast tumor suppressor. Nat Commun. 2019; 10: 1398.
16. Jain K, Fraser CS, Marunde MR, Parker MM, Sagum C, Burg JM, et al. Characterization of the plant homeodomain (PHD) reader family for their histone tail interactions. Epigenetics & chromatin. 2020; 13: 3.
17. Pohl SG, Brook N, Agostino M, Arfuso F, Kumar AP, Dharmarajan A. Wnt signaling in triple-negative breast cancer. Oncogenesis. 2017; 6: e310.
18. Li J, Zhou BP. Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer. 2011; 11: 49.
19. Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson’s disease. Neuron. 2015; 85: 257-73.
20. Xu L, Lin DC, Yin D, Koefler HP. An emerging role of PARK2 in cancer. Journal of molecular medicine (Berlin, Germany). 2014; 92: 51-62.
21. Liu J, Zhang C, Zhao Y, Yue X, Wu H, Huang S, et al. Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression. Nat Commun. 2017; 8: 1823.
22. LaGory EL, Giaccia AJ. The ever-expanding role of HIF in tumour and stromal biology. Nat Cell Biol. 2016; 18: 356-65.
23. Liu J, Zhang C, Wu H, Sun XX, Li Y, Huang S, et al. Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression. The Journal of clinical investigation. 2020; 130: 3253-69.
He L, Liu X, Yang J, Li W, Liu S, Liu X, et al. Imbalance of the reciprocally
regulated Warburg effect in hepatocellular carcinoma revealed by exome sequencing. Hepatology (Baltimore, Md). 2021; 73: 1816-35.

Xiong J, Wei B, Ye Q, Liu W. Mira-30a-5p/UBE3C axis regulates breast cancer cell proliferation and migration. Biochem Biophys Res Commun. 2019; 516: 16-23.

Jiang JH, Liu YF, Ke AW, Gu FM, Yu Y, Dai Z, et al. Clinical significance of the ubiquitin ligase UBE3C in hepatocellular carcinoma revealed by exome sequencing. Hepatology (Baltimore, Md). 2014; 59: 2166-77.

Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P, et al. BAP1 links metabolic suppression to breast cancer metastasis. Cancer Lett. 2019; 443: 125-34.

Aloni-Grinstein R, Shetzer Y, Kaufman T, Rotter V. p53: the barrier to cancer stem cell formation. FEBS letters. 2014; 588: 2580-9.

Zhang Y, Xu J, Fu H, Wei Z, Yang J, Liu X. UBE3C promotes proliferation and inhibits apoptosis by activating the β-catenin signaling via degradation of AXIN in gastric cancer. Carcinogenesis. 2021; 42: 285-93.

Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annual review of cell and developmental biology. 2006; 22: 247-69.

Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002; 420: 647-54.

Gu J, Mao W, Ren W, Xu F, Zhu Q, Lu C, et al. Ubiquitin-protein ligase E3C maintains non-small-cell lung cancer stemness by targeting ATMIN/p53 complex. Cancer Lett. 2019; 443: 125-34.

Kaminski N, Rosetta F, Chen T, Zhang Y, Wu X, and Lee C. USP7 stabilizes EZH2 and enhances cancer malignant progression. American journal of cancer research. 2020; 10: 299-313.

Dai X, Lu L, Deng S, Meng J, Wan C, Huang J, et al. USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated macrophages in Lung Cancer. Theranostics. 2020; 10: 9332-47.

Yu FX, Zhao B, Guan KL. Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell. 2015; 163: 811-832.

Chen XX, Yin Y, Cheng JW, Huang A, Hu B, Zhang X, et al. BAP1 acts as a tumor suppressor. Nat Commun. 2015; 6: 6482-9.

Zhu XN, He P, Zhang L, Yang S, Zhang HL, Zhu D, et al. FBXO22 mediates MET signaling in colorectal cancer cells. Mol Carcinog. 2021; 60: 2491-504.
acetylation promoting hypoxia-induced tumour progression. Nat Commun. 2016; 7: 13644.

Ma M, Yu N. Ubiquitin-specific protease 7 expression is a prognostic factor in epithelial ovarian cancer and correlates with lymph node metastasis. Oncol Targets Ther. 2016; 9: 1559-69.

Yang X, Jin J, Yang J, Zhou L, Mi S, Qi G. Expression of Ubiquitin-specific protease 7 in oral squamous cell carcinoma promotes tumor cell proliferation and invasion. Genetics and molecular biology. 2014; 37: 20020135.

Ye M, He J, Zhang J, Liu B, Liu X, Xie L, et al. USP7 promotes hepatoblastoma progression through activation of PI3K/AKT signaling pathway. Cancer biomarkers : section A of Disease markers. 2021; 31: 107-17.

Xiang M, Liang X, Xie Z, Liu J, Zhao S, et al. Pharmacological inhibition of USP7 suppresses growth and metastasis of melanoma cells in vitro and in vivo. J Cell Mol Med. 2021; 25: 9228-40.

Jing X, Chen Y, Chen Y, Shi G, Lv S, Chen N, et al. Down-regulation of USP8 inhibits Cholangiocarcinoma Cell Proliferation and Invasion. Cancer management and research. 2020; 12: 2185-94.

Qiu H, Kong J, Cheng Y, Li G. The expression of ubiquitin-specific peptide 8 and its prognostic role in patients with breast cancer. J Cell Biochem. 2018; 119: 719-25.

Liu L, Yao D, Zhang P, Ding W, Zhang X, Zhang C, et al. Deubiquitinase USP9X promotes cell migration, invasion and inhibits apoptosis of human pancreatic cancer. Oncology reports. 2017; 38: 1533-7.

Wu Y, Yu X, Yi X, Wu K, Dwayne S, Atefi M, et al. Ablantar Phosphorylation of SMAD3/4 Translocated USP8/USP21 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis. Cancer Res. 2013; 77: 1383-94.

Yuan T, Chen Z, Yan F, Qian M, Luo H, Ye S, et al. Deubiquitinating enzyme USP10 promotes hematopoietic cell carcinoma metastasis through deubiquitination and stabilizing Smad proteins. Cell Res. 2010; 20: 197-210.

Li B, Qi ZP, He DL, Chen ZH, Liu JY, Wong MW, et al. NLRP7 deubiquitination by USP10 promotes tumor progression and tumor-suppressor-associated macrophage polarization in colorectal cancer. J Exp Clin Cancer Res. 2021; 40: 179.

Sun J, Ou B, Zhao S, Liu X, Song L, Liu X, et al. USP11 promotes growth and metastasis of colorectal cancer through USP11-dependent FOXO1 and YAP signaling. Aging. 2019; 11: 9643-60.

Li J, Yuan S, Norgard JR, Yan F, Yamazoe T, Blanco A, et al. Tumor Cell-Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer. Cancer Immunol Res. 2020; 8: 282-91.

Kosinsky RL, Zerche M, Saul D, Wang X, Wolln, Wegwis, et al. USP22 exerts tumor-suppressive functions in colorectal cancer by decreasing mTOR expression and its prognostic role in patients with breast cancer. J Cell Biochem. 2018; 119: 51-61.

Li J, Tan Q, Yan M, Liu L, Lin H, Zhao F, et al. miRNA-200c inhibits invasion and metastasis of human non-small cell lung cancer by directly targeting ubiquitin specific peptidase 25. Molecular cancer. 2014; 13: 166.

Li L, Zhou H, Zhu H, Liu Z. USP26 promotes esophageal squamous cell carcinoma metastasis through SMAD4 interaction. Front Cell Neurosci. 2019; 46: 52-60.

Zhao LJ, Zhang T, Feng XJ, Chang J, Suo FZ, Ma JL, et al. USP28 contributes to the proliferation and metastasis of gastric cancer. J Cell Biochem. 2018.

Fügel D, Görrlich A, Kietzmann T. GSK-3β regulates cell growth, migration, and angiogenesis via PI3K and Wnt/Vβ signaling. Front Oncol. 2020; 20: 116672.

Gan Q, Shao J, Cao Y, Lei J, Xie P, Ge J, et al. USP33 regulates c-Met expression by deubiquitinating SPI1 to facilitate metastasis in hepatocellular carcinoma. Life Sci. 2020; 261: 118316.

Buss R, Faronato M, Hammond DE, Urbe S, Clague MJ. Deubiquitinase activities required for hepatocyte growth factor-induced scattering of epithelial cells. Curr Biol. 2009; 19: 1463-6.

Huang Z, Wen P, Kong R, Cheng H, Zhang B, Quan C, et al. USP33 mediates Sirt1-Robo signaling in inhibiting colorectal cancer cell migration. Int J Cancer. 2015; 136: 1792-802.

Xia Y, Wang L, Xu Z, Kong R, Wang F, Yin K, et al. Reduced USP33 expression in gastric cancer decreases inhibitory effects of Sirt1-Robo signalling on cell migration and EMT. Cell Prolif. 2019; 52: e12606.

Cai J, Li M, Wang X, Li L, Li Q, Hou Z, et al. USP37 Promotes Lung Cancer Cell Migration by Stabilizing Snail Protein via Deubiquitination. Front Genet. 2019; 10: 1234.

Liu T, Li B, Feng X, Yan S, Liu L, Liu D, et al. Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity. Journal of Experimental & Clinical Cancer Research. 2018; 37.

Xiao Z, Zhang L, Kim J, Han Y, Yang S, et al. USP37 in a SNAI1 deubiquitinase. American journal of cancer research. 2019; 9: 2749-59.

Liu T, Sun B, Zhao X, Li Y, Zhao X, Liu Y, et al. USP44+ Cancer Stem Cell Subclones Contribute to Breast Cancer Aggressiveness by Promoting Vasculogenic Mimicry. Mol Cancer Ther. 2015; 14: 2121-31.

Park JM, Lee JE, Park CM, Kim JH. USP44 Promotes the Tumorigenesis of Prostate Cancer Cells through EZH2 Protein Stabilization. Molecules and cells. 2019; 42: 17-27.

Tian M, Zhu R, Ding F, Liu Z. Ubiquitin-specific peptidase 46 promotes tumor metastasis through stabilizing ENO1 in human esophageal squamous cell carcinoma. Exp Cell Res. 2020; 395: 112188.
135. Fraile JM, Campos-Iglesias D, Rodríguez F, Estapay Y, Freije JM. The deubiquitinase USP54 is overexpressed in colorectal cancer stem cells and promotes intestinal tumorigenesis. Oncotarget. 2016; 7: 74427-34.

136. Zhou H, Liu Y, Zhu R, Ding F, Cao X, Lin D, et al. OTUBI promotes esophageal squamous cell carcinoma metastasis through modulating Snail stability. Oncogene. 2018; 37: 3356-68.

137. Zhou Y, Wu J, Fu X, Du W, Zhou L, Meng X, et al. OTUBI promotes metastasis and serves as a marker of poor prognosis in colorectal cancer. Molecular Cancer. 2014; 13: 258.

138. Li J, Cheng D, Zhu M, Yu H, Pan Z, Liu L, et al. OTUB2 stabilizes U2AF2 to promote the Warburg effect and tumorigenesis via the AKT/mTOR signaling pathway in non-small cell lung cancer. Theranostics. 2019; 9: 179-95.

139. Zhang Z, Du J, Wang S, Shao L, Jin K, Li F, et al. OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ. Mol Cell. 2019; 73: 7-21 e7.

140. Zhang F, Li C, Li H, Yuan L, Dai H, Peng Z, et al. Ubiquitin ligase CHIP regulates OTUD3 stability and suppresses tumour metastasis in lung cancer. Cell Death Differ. 2020; 27: 3177-95.

141. Yuan L, Lv Y, Li H, Gao H, Song S, Zhang Y, et al. Deubiquitylase OTUD3 regulates PTEN stability and suppresses tumorigenesis. Nat Cell Biol. 2015; 17: 1169-81.

142. Liu X, Zhang X, Peng Z, Li C, Wang Z, Wang C, et al. Deubiquitylase OTUD6B Governs pVHL Stability in an Enzyme-Independent Manner and Suppresses Hepatocellular Carcinoma Metastasis. Adv Sci (Weinh). 2020; 7: 1902040.

143. Lin DD, Shen Y, Qiao S, Liu WW, Zheng L, Wang YN, et al. Upregulation of OTUD7B (Cezanne) Promotes Tumor Progression via AKT/VEGF Pathway in Lung Squamous Carcinoma and Adenocarcinoma. Front Oncol. 2019; 9: 862.

144. Qin J, Zhou Z, Chen W, Wang C, Zhang H, Ge G, et al. BAP1 promotes breast cancer cell proliferation and metastasis by deubiquitinating KL5. Nat Commun. 2015; 6: 8471.

145. Amato E, Mafficini A, Hiraibayashi K, Lawlor RT, Fassan M, Vicentini C, et al. Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas. J Pathol. 2019; 247: 123-34.

146. Gupta MP, Lane AM, DeAngelis MM, Mayne K, Crabtree M, Gragoudas ES, et al. Clinical Characteristics of Uveal Melanoma in Patients With Germline BAP1 Mutations. JAMA Ophthalmol. 2015; 133: 881-7.

147. Harbour JW, Osklen MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science (New York, NY). 2010; 330: 1410-3.

148. de Jel MM, Schott M, Lamm S, Neuhuber W, Kuphal S, Bosserhoff AK. Loss of CYLD accelerates melanoma development and progression in the Tg(Grm1) melanoma mouse model. Oncogenesis. 2019; 8: 56.

149. Millani de Marval P, Lutfeali S, Jin JY, Leshin B, Selim MA, Zhang JY. CYLD inhibits tumorigenesis and metastasis by blocking JNK/AP1 signaling at multiple levels. Cancer prevention research (Philadelphia, Pa). 2011; 4: 851-9.

150. Massoumi R, Kuphal S, Hellerbrand C, Haas B, Wild P, Spruss T, et al. Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med. 2009; 206: 221-32.

151. Goto Y, Zeng L, Yeom CJ, Zhu Y, Morinibu A, Shinomiya K, et al. UCHL1 accelerates melanoma mouse model. Oncogenesis. 2019; 2016; 33: 1410-3.

152. Jang MJ, Baek SH, Kim JH. UCH-L1 promotes cancer metastasis in prostate cancer cells through EMT induction. Cancer Lett. 2011; 302: 128-35.

153. Kim HJ, Kim YM, Lim S, Nam YK, Jeong J, Kim HJ, et al. Ubiquitin C-terminal hydroxylase-L1 is a key regulator of tumor cell invasion and metastasis. Oncogene. 2009; 28: 117-27.

154. Wang W, Zou L, Zhou D, Zhou Z, Tang F, Xu Z, et al. Overexpression of ubiquitin carboxyl terminal hydrolase-L1 enhances multidrug resistance and invasion/metastasis in breast cancer by activating the MAPK/Erk signaling pathway. Mol Carcinog. 2016; 55: 1329-42.

155. Seliger B, Fedorushchenko A, Brenner W, Ackermann A, Atkins D, Hanash S, et al. Ubiquitin COOH-terminal hydrolase 1: a biomarker of renal cell carcinoma associated with enhanced tumor cell proliferation and migration. Clin Cancer Res. 2007; 13: 27-37.

156. Liu S, González-Prado R, Zhang M, Geurink PP, Kooij R, Iyengar PV, et al. Deubiquitinating Activity Profiling Identifies UCHL1 as a Candidate Oncoprotein That Promotes TGFβ-Induced Breast Cancer Metastasis. Clin Cancer Res. 2020; 26: 1460-73.

157. Liu D, Song Z, Wang X, Ouyang L. Ubiquitin C-Terminal Hydroxide L5 (UCHL5) Accelerates the Growth of Endometrial Cancer via Activating the Wnt/J-Catenin Signaling Pathway. Front Oncol. 2020; 10: 865.

158. Huang M, Xiong H, Luo D, Xu B, Liu H. CSN5 upregulates glycolysis to promote hepatocellular carcinoma metastasis via stabilizing the HK2 protein. Exp Cell Res. 2020; 388: 111876.

159. Zhang S, Hong Z, Chai Y, Liu Z, Du Y, Li Q, et al. CSN5 promotes renal cell carcinoma metastasis and EMT by inhibiting ZEB1 degradation. Biochem Biophys Res Commun. 2017; 488: 101-8.

160. Hou J, Deng Q, Zhou J, Li J, Zhang Y, Pan P, et al. CSN6 controls the proliferation and metastasis of glioblastoma by CHIP-mediated degradation of EGFR. Oncogene. 2017; 36: 1134-44.

161. Mao Z, Sang MM, Chen C, Zhu WT, Gong YS, Fei DS. CSN6 Promotes the Migration and Invasion of Cervical Cancer Cells by Inhibiting Autophagic Degradation of Cathepsin L. Int J Biol Sci. 2015; 19: 1310-24.

162. Zou H, Chen H, Zhou Z, Wan Y, Liu Z. ATXN3 promotes breast cancer metastasis by deubiquitinating KL4. Cancer Lett. 2019; 467: 19-28.